New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
12:25 EDTICPT, ICPT, ICPT, GILD, GILD, GILD, RPTP, RPTP, RPTP, CNAT, CNAT, CNATSummer Street biotech analyst to hold an analyst/industry conference call
Specialty Pharma & Biotech Analyst Molloy and Chief Scientific Officer Classen, along with an MCRI consultant, provide a preview of Intercept Pharmaceuticals upcoming FLINT trial data from the NIH in July on an Analyst/Industry conference call. Relevant companies ICPT, GILD, RPTP and CNAT may be included on the Analyst/Industry conference call to be held on June 17 at 1 pm.
News For ICPT;GILD;RPTP;CNAT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
09:35 EDTGILDGilead mentioned cautiously at Cleveland Research
Subscribe for More Information
January 22, 2015
07:17 EDTICPTIntercept price target lowered to $300 from $500 at Deutsche Bank
Subscribe for More Information
January 20, 2015
16:00 EDTGILDOptions Update; January 20, 2015
iPath S&P 500 VIX Short-Term Futures down 36c to 35.12 Option volume leaders: AAPL TSLA TWTR GILD NFLX MGM ABX AMAT JNJ C according to Track Data.
09:38 EDTGILDActive equity options trading
Subscribe for More Information
January 16, 2015
14:54 EDTGILDGilead at high of day, up 3% after reaching hep C drug pact with Aetna
14:46 EDTGILDAetna, Gilead confirm discount pricing for hepatitis C drugs Harvoni, Sovaldi
Subscribe for More Information
13:05 EDTGILDGilead granted orphan status for pulmonary arterial hypertension treatment
The FDA granted Gilead orphan status for its treatment of pulmonary arterial hypertension. Reference Link
09:37 EDTGILDActive equity options trading
Subscribe for More Information
January 15, 2015
11:20 EDTGILDGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
January 14, 2015
09:36 EDTGILDActive equity options trading
Subscribe for More Information
07:08 EDTGILDGilead still poised to beat 2015 estimates, says RBC Capital
Subscribe for More Information
January 13, 2015
16:00 EDTGILDOptions Update; January 13, 2015
iPath S&P 500 VIX Short-Term Futures up 66c to 34.42. Option volume leaders: AAPL JNJ CELG WFM TSLA TWTR AMZN GILD according to Track Data.
12:15 EDTGILDExpress Scripts CEO says Gilead relationship 'important' going forward
Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.
12:10 EDTGILDExpress Scripts CEO says 'never stopped talking to Gilead'
Subscribe for More Information
11:43 EDTGILDGilead says negotiations ongoing with major U.S. payors for Harvoni
Subscribe for More Information
11:10 EDTGILDGilead drops, levels to watch
Subscribe for More Information
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL AMD AA TWTR GILD C CELG TSLA GOOG
07:42 EDTGILDJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
January 12, 2015
09:34 EDTGILDActive equity options trading
Subscribe for More Information
08:13 EDTICPTIntercept plans to initiate PSC Program Biliary Atresia Phase in 2H15
Intercept provided a clinical update on obeticholic acid, or OCA, a novel bile acid analog and first-in-class agonist of the farnesoid X receptor, or FXR, as well as planned 2015 milestones and other general business updates. OCA is currently being developed for the treatment of several chronic liver diseases, including primary biliary cirrhosis, or PBC, nonalcoholic steatohepatitis, or NASH, and primary sclerosing cholangitis, or PSC. The completion of PBC Program NDA and MAA filings planned in 1H15. The NASH Program Phase 3 program initiation planned in 1H15 and Japan Phase 2 trial data expected at the end of 2015. The PSC Program Biliary Atresia: Phase 2 initiation planned in 2H15 and INT-767: Phase 1 initiation planned for the end of 2015. Intercept ended 2014 with approximately $240M in cash and investments. For FY15, the company projects adjusted operating expenses in the range of $180M-$200M, which excludes stock-based compensation and other non-cash items. These expenses will support the clinical development program for OCA in PBC, NASH and PSC, expansion of our clinical, regulatory, medical affairs and commercial infrastructure in the United States and Europe, expansion of OCA manufacturing activities, as well as advancement of INT-767 and other preclinical pipeline programs. Adjusted operating expense, as presented above, is a non-GAAP financial measure. The company anticipates that stock-based compensation expense will represent the most significant non-cash item that is excluded in adjusted operating expenses as compared to operating expenses under GAAP.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use